Text Size

VX-950 and Peginterferon for Hepatitis C

This study has been completed.
Sponsor:
Information provided by:
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:
NCT00251199
First received: November 7, 2005
Last updated: December 17, 2007
Last verified: December 2007
History of Changes
  Purpose

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.


Condition Intervention Phase
Hepatitis C
 Drug: VX-950
Drug: peginterferon
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C

Resource links provided by NLM:

Drug Information available for: Telaprevir
U.S. FDA Resources

Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Viral kinetics

Secondary Outcome Measures:
  • Assess the safety of VX-950 in combination with peginterferon

Estimated Enrollment: 20
Study Start Date: October 2005
Study Completion Date: March 2006
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • infected with Hepatitis C virus

Exclusion Criteria:

  • contraindications to peginterferon therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00251199

Locations
Germany
Call for information
Homburg/Saar, Germany
Netherlands
Call for information
Amsterdam, Netherlands
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Investigators
Study Director: Medical Monitor Vertex Pharmaceuticals Incorporated
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00251199     History of Changes
Other Study ID Numbers: VX05-950-103
Study First Received: November 7, 2005
Last Updated: December 17, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
 Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on June 17, 2013